Infertility is a medical condition that can cause psychological, physical, mental, spiritual, and medical detriments to the patient. The unique quality of this medical condition involves affecting both the patient and the patient's partner as a couple. Although male infertility is an important part of any infertility discussion, this paper will review the evaluation, management, and treatment of female infertility. One must understand normal fecundability, the probability of achieving pregnancy in one menstrual cycle, in order to understand infertility. This basic understanding will assist the healthcare team in properly counseling the patient on referrals and providing basic education and understanding of this medical condition.
The research community has established a fecundability rate multiple times, which has helped establish normal pregnancy rates to assist in the diagnosis of infertility. The largest study identified that 85% of women will conceive within 12 months. Based on this study's findings, fecundability is 25% in the first three months of unprotected intercourse and then decreased to 15% for the remaining nine months. This research has helped the American Society of Reproductive Medicine (ASRM) establish when a couple should undergo an evaluation for infertility. The ASRM recommends initiating an evaluation for infertility after the failure to achieve pregnancy within 12 months of unprotected intercourse or therapeutic donor insemination in women younger than 35 years or within 6 months in women older than 35.
The World Health Organization (WHO) performed a large multinational study to determine the gender distribution and etiologies of infertility. In 37% of infertile couples, female infertility was the cause, in 35% of couples, both male and female causes were identified, in 8% male factor infertility, and 5% were given the diagnosis. In the same study, the most common identifiable factors of female infertility are as follows:
Each of these causes will be further investigated in later portions of this paper. Male and unknown factors are outside the scope of this paper and will be discussed elsewhere. Even though these factors are not discussed here, it is important to realize that male factor infertility represents a substantial portion of the identifiable factors causing infertility.
In a study conducted by the National Survey of Family Growth that interviewed 12,000 women in the United States, the prevalence of infertility decreased with the increase in the woman’s age. As a woman gets older, her chances of infertility increases. In women aged 15 to 34 years, infertility rates ranged from 7.3 to 9.1%. In women ages 35 to 39 years old, the infertility rates increased to 25%. Lastly, women from ages 40 to 44 years had a 30% chance of infertility. Worldwide, infertility rates are higher in Eastern Europe, North Africa, and the Middle East. Worldwide, 2% of women aged 20 to 44 were never able to have a live birth, and 11% with a previous live birth were unable to have an additional birth.
Ovulatory disorders make up 25% of the known causes of female infertility. Oligo-ovulation or anovulation results in infertility because no oocyte will be released monthly. In the absence of an oocyte, there is no opportunity for fertilization and pregnancy. To help with treatment and further classification, the World Health Organization subdivided ovulatory disorders into four classes:
Hypothalamic amenorrhea or functional hypothalamic amenorrhea (FHA) is associated with eating disorders and excessive exercise, which results in a decrease in hypothalamic GnRH secretion. The decreased caloric intake, associated weight loss, or excessive exercise leads to elevated cortisol, which causes a suppression of GnRH. The decreased or absent pulsatility of GnRH results in a decrease in the release of gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), from the anterior pituitary gland. These two deficiencies result in abnormal follicle growth, anovulation, and low estrogen levels. The FSH and LH will have variations ranging from normal to low, but the ratio of the hormones will resemble that of a prepubertal female, with FSH higher than LH.
The most common type of Normogonadotropic normoestrogenic anovulation is PCOS. PCOS accounts for 80-85% of all anovulatory patients and affects 8% of all reproductive-aged females. PCOS can be diagnosed using the Rotterdam criteria, which requires at least two of the three below listed criteria in the absence of other pathological causes:
Infertility caused by PCOS is thought to be associated with a dysfunction in the development of a mature follicle leading to anovulation. The FSH and estrogen will be within normal laboratory limits. The LH can either be normal or elevated. The pathophysiology behind PCOS and infertility is not well understood, classically, abnormal pulsatility of GnRH is described as a possible underlying cause. Correlating the high of arrested follicles and polycystic appearing ovaries is the elevation of anti-Mullerian hormone (AMH).
Hypergonadotropic hypoestrogenic anovulation is the category of premature ovarian insufficiency and ovarian resistance associated with the female’s age. As mentioned before, a woman’s age affects fertility; this is due to a well-studied phenomenon of a steady decline in the quality and quantity of the patient’s oocytes. In terms of quantity, the female fetus at 20 weeks gestation, has roughly 6 million follicles, the newborn has approximately 1 million follicles, and at the onset of puberty, the number of follicles decreases to 300,000. The rate of follicle loss continues through a woman’s life and begins to increase in rate round her mid-thirties. External factors are also associated with decreased follicular quantity. The most notable and highly researched is cigarette smoking. Fecundability and follicular quantity are both inversely proportional to the amount of cigarette smoking. Early menopause (age less than 40 years) is also associated with cigarette smoking; there is a more than 30% increase in early menopause among ever-smokers.
Ovarian quality is also essential to overall fertility. The loss of the oocyte quality throughout a woman’s life is associated with meiotic nondisjunction, resulting in aneuploidy. This is thought to be related to the accumulative damage throughout life and age-related changes in the granulosa cells. As women ages, there is a significant increase in the number of meitotic nondisjunction events and corresponding aneuploid or chromosomally abnormal oocytes and embryos.
Primary ovarian insufficiency (POI) is defined as hypergonadotropic hypogonadism before the age of 40. This disease is characterized by a lack of folliculogenesis, a decrease in estrogen, loss of oocytes, and infertility. The most common cause of POI is Turner syndrome, monosomy of the sex chromosomes leading to a 45X karyotype. Further discussion of Turner syndrome is outside the scope of this manuscript.
As mentioned above, the WHO recognizes prolactinemia as a leading cause of female infertility; however, the ASRM recently published guidelines that the initial workup does not need to include prolactin. Prolactin causes suppression of hypothalamic GnRH secretion leading to a low LH, resulting in anovulation, corresponding oligomenorrhea, or amenorrhea. Prolactin serum values of 20-50 ng/mL cause insufficient progesterone release from the corpus luteum, which shortens the luteal phase. Although controversial, prolactinemia is described as an etiology of luteal phase defects, which may lead to infertility. Prolactin values of 50-100 ng/mL cause amenorrhea or oligomenorrhea due to abnormal feedback on the hypothalamic-pituitary-ovarian axis. A concentration greater than 100 ng/mL are associated with overt hypogonadism and amenorrhea and most commonly associated with pituitary adenomas.
Endometriosis is defined as endometrial tissue outside the uterine cavity. The diagnosis is based on the histological identification endometrial glands and/or stroma outside the uterus. Endometriosis is most commonly found in the pelvis but can spread throughout the entire abdomen and affects 10% to 15% of reproductive-age women. Of women with endometriosis, 40% to 50% will experience infertility. Endometriosis is categorized in four stages, according to the American Society of Reproductive Medicine, with stage I being minimal and stage IV severe. Endometriosis is known to cause infertility, but the pathophysiology is thought to change according to the stage. For stages I and II, infertility is believed to be associated with inflammation with increased production of prostaglandins and cytokines, macrophages, and natural killer cells.  The inflammation impairs ovarian and tubal function resulting in defective follicular formation, fertilization, and implantation. Stages III and IV are associated with pelvic adhesions and/or masses that distort pelvic anatomy; this will inherently impair tubal motility, oocyte release, and sperm motility. Also, advanced endometriosis is hypothesized to impair folliculogenesis, which reduces the fertilization potential.
Pelvic and tubal adhesions, along with uterine and tubal abnormalities account for a large portion of female infertility. Infectious processes within the abdomen are the leading cause of pelvic/tubal adhesions; the most common infectious process to affect infertility is pelvic inflammatory disease (PID). The microorganism that carries the greatest risk of infertility in association with PID is Chlamydia trachomatis. One in 4 women with tubal factor infertility will have positive antibodies to chlamydia, which are inversely proportional to pregnancy rates. The number of PID episodes, as well as the severity, play a role in the likelihood of infertility. One study demonstrated that the pregnancy rates following PID were 89% after 1 episode, 77% after two episodes, and 46% after three episodes. In terms of PID severity of mild, moderate, and severe, the livebirths rates were 90%, 82%, and 57% respectfully.
Hydrosalpinges, are a tubal abnormality caused by acute and chronic inflammation that damages the structural integrity of the fallopian. This damage leads to tubal obstruction, which blocks the distribution of physiologic fluid in the fallopian tube and results in an accumulation of fluid. The belief is that hydrosalpinges impair fertility through the retrograde flow of toxins and prostaglandins into the endometrium, creating a hostile environment for implantation by impairing endometrial receptivity. The literature has demonstrated that patients undergoing in-vitro fertilization have a 50% decrease in pregnancy if a hydrosalpinx is present.
Uterine causes of infertility are associated with either space-occupying lesions or reduced endometrial receptivity. In regards to uterine leiomyomas (fibroids), one meta-analysis demonstrated that only submucosal or intracavitary fibroids impaired implantation and pregnancy rates compared to other infertile controls. Congenital uterine abnormalities (CUA), although rare, are also associated with infertility. Most commonly found are uterine septums, which are also associated with recurrent pregnancy loss. Interestingly, one study demonstrated that the prevalence of CUA in the fertile and infertile population is the same. Infertility due to CUA is thought to account for roughly 8% of the female causes of infertility; however, 25% of women with late first trimester or second-trimester miscarriages are found to have CUAs. A detailed discussion on the classifications and pathophysiology of CUAs is outside the scope of this manuscript.
Infertility evaluation is indicated in women with unsuccessful pregnancy after 12 months of unprotected regular intercourse or 6 months if the female is over 35 years old. This article is focusing on female infertility, but it is essential to remember that a male infertility evaluation is needed and should be initiated at the same time. For women planning to use donor sperm, they should receive the same female infertility workup before inseminations. The key aspects of the history of the infertile woman are listed below:
The physical exam should include the following:
The 5 diagnostic evaluation categories are:
The evaluation and interpretation of a semen analysis are outside the scope of this review; however, it cannot be reiterated enough on the importance of this test as part of the initial evaluation before initiating treatments.
Assessment of ovarian function can be as simple as the menstrual cycle history. Women with predictable, regular cycles and predictable menstrual flow, as well as molimina (bloating, fatigue, breast tenderness), are more than likely ovulating. At-home urinary LH predictor kits detect a mid-cycle LH surge, which is indirect evidence of ovulation and assists in identifying the fertile window. Ovulation can also be detected by a cycle day 21 progesterone serum level, or more accurately, a mid-luteal phase progesterone level. The lab should be taken approximately 1 week before menses, and a progesterone lab value of greater than 3 ng/mL is evidence of ovulation. A more invasive, more accurate, but likely unnecessary means of determining ovulation is daily ultrasounds for following the growth and disappearance of a follicle.
There are multiple available tests to assess ovarian reserve, and this review will only discuss the two most common: Cycle day 3 FSH and estradiol, and Anti-Mullerian hormone (AMH). The theory of day 3 FSH and estradiol is that women with good ovarian reserve have early sufficient ovarian hormones from small follicles to allow FSH to remain at a lower level. According to multiple examples in the literature, it is most important to identify women with a reduced follicle count that produces insufficient hormones, causing a lack of inhibition, resulting in an elevated FSH. FSH levels less than 10 IU/mL demonstrate likely normal ovarian reserve, 10 to 20 IU/mL is intermediate, and an FSH greater than 20 IU/mL is a poor prognosis for spontaneous ovulation due to low ovarian reserve. The pregnancy rates per natural menstrual cycle, corresponding to the FSH levels above, according to one study, are 32%, 17% to 19%, and 3%. Day 3 estradiol less than 80 pg/mL is considered normal with adequate ovarian reserve. Values greater than 80 pg/mL resulted in lower pregnancy rates and values >100 pg/mL had a 0% pregnancy rate.
AMH is a hormone expressed by preantral and antral follicles that represent a marker of ovarian function that can be measured at any time during a woman’s cycle. The AMH levels will gradually decline throughout a woman’s natural reproductive life to the point of undetectable levels at menopause. AMH levels seem to be a good predictor of exogenous gonadotropin response:
It is important to remember that the ovarian reserve tests that are currently available are reliable in predicting ovulation induction difficulties but are not diagnostic in predicting live birth and should not be used to exclude patients from in vitro fertilization (IVF) treatment.
Antral follicle counts, measuring the number of follicles less than 9mm in the ovaries with transvaginal ultrasound in the early follicular phase, is also an accurate measure of ovarian reserve and predictive of ovarian response to stimulation.
The gold standard for the evaluation of tubal patency is laparoscopy with chromopertubation. Laparoscopy is indicated as a first-line diagnostic test for suspected pelvic adhesions, endometriosis, or other pelvic pathologies; however, due to high specificity and being less invasive, the hysterosalpingogram (HSG) is more commonly used for the first-line evaluation for tubal patency and abnormalities. The ability to detect abnormalities is best for proximal occlusion, followed by distal occlusions; however, the HSG has poor predictability for intrauterine and tubal adhesions. Another added benefit of the HSG is an increase in pregnancy and live birth rates with oil-soluble media. A meta-analysis showed that after HSG, pregnancy and live birth rates increased compared to controls (OR 2.98, 95% CI 1.05- 6.37).
The gold standard for the assessment of the uterine cavity is hysteroscopy, which allows direct visualization of the intrauterine pathology and provides an opportunity for immediate surgical correction. Although hysteroscopy is considered the gold standard, a less invasive approach is more commonly utilize with a saline infusion sonogram (SIS). The SIS is highly sensitive and specific for all intrauterine abnormalities and is adequate as a screening tool before infertility treatment, with or without 3-D model rendering.
Women with extremes in body mass index (BMI) frequently present with infertility and ovulatory dysfunction. Women with a BMI of less than 17 kg/m2 with a history of intense exercise regiments or women with eating disorders are likely to develop hypogonadotropic hypogonadism, which causes deceased pituitary gonadotropin secretions. In The United States, controlled ovarian stimulation using exogenous gonadotropins are used to induce ovulation; however, in Europe, women who fail to respond to therapy can receive pulsatile GnRH therapy. One study demonstrated the importance of behavioral change in inducing ovulation. Of the women who received individual directed therapy to correct energy deficiencies or behavior problems, 87% resumed regular ovarian function with correction of the abnormal BMI.
Women with a BMI greater than 27 kg/m^2 with anovulation can improve ovulation with weight loss alone. Multiple studies have shown that a loss of 10% of body weight will restore normal ovulation in 50-100% of women in less than 1 year. Even though weight loss is important for many aspects of a patient's life, one study showed that obese women who received counseling and interventions for weight loss before infertility treatment did not have higher pregnancy or live birth rates compared to obese women who had infertility treatment without weight-loss interventions. Therefore, a specific BMI is not required to initiate fertility treatment.
Controlled Ovarian Hyperstimulation
The first-line medication for infertility of unknown origin and the medication most providers are aware of is clomiphene citrate (CC). Clomiphene is a selective estrogen receptor modulator (SERM) with estrogen antagonist and agonist effects that ultimately increase gonadotropin release from the anterior pituitary. Clomiphene is effective in treating WHO class 2 anovulation, but ineffective in WHO class 1 and class 3 anovulation. Clomiphene is dosed starting at 50mg starting on cycle day 2, 3, 4, or 5 for 5 sequential days. The couple is encouraged to have intercourse every other day for one week beginning 5 days after the last pill. However, the odds for pregnancy may be increased when clomiphene is combined with intrauterine insemination (IUI). There is little difference in the results of ovulation, pregnancy, or live birth in regards to which day the medication is started, between cycle days 2 to 5.
Another commonly used oral medication for ovulation induction is letrozole. Letrozole is an aromatase inhibitor that prevents the production of estrogen by preventing the conversion of androstenedione and testosterone to estrone and estradiol. Letrozole is FDA indicated for the extended adjuvant treatment of breast cancer and its use for ovulation induction is considered off-label. However, there is an abundance of scientific literature and multiple committee opinions that support both the efficacy and safety of its use in ovulation induction. Letrozole is dosed starting at 2.5, 5, or 7.5 mg/day on cycle days 3, 4, 5, 6, 7 with intercourse every other day 5 days after completion of the medication, which is similar to clomiphene. According to ACOG, letrozole should be considered first-line treatment for women with PCOS over clomiphene. The benefits of letrozole over clomiphene are:
Letrozole's beneficial profile compared to clomiphene may replace clomiphene as a first-line treatment in the future.
Gonadotropin therapy is a more intensive medical regimen that is used for WHO Class 1, 2, or 3 anovulatory disorders. Gonadotropins are beneficial as a second-line treatment option for women who failed to conceive after multiple cycles of clomiphene. There is one study that showed an increased live birth rate with gonadotropins compared to continued clomiphene usage. There are multiple dosing protocols that are used depending on the provider's preferences, and
upon the infertility treatment decided. Those protocols are outside the scope of this review. However, it is important to discuss that while using more invasive and intensive gonadotropins, close monitoring is required. Transvaginal ultrasounds are used to monitor follicular growth every 2 to 3 days during the late follicular phase to evaluate for mature follicles. A mature follicle is one that is greater than 18mm in diameter and estradiol of greater than 200 pg/mL. Once a mature follicle is identified, recombinant HCG 250mg subcutaneous injection or intramuscular injection of 10,000U of urinary-derived HCG is given to trigger ovulation. Once the trigger shot is given, an IUI occurs 24-36 hours later. IUIs can be used in combination with all the ovarian induction agents, and IUI with medication is encouraged to increase pregnancy rates, which will be discussed below. There is unclear evidence as to the superiority of allowing a natural LH surge versus HCG trigger prior to IUI. A meta-analysis completed in 2010 showed that there was no clear evidence of one treatment option over the other and the treatment choice should be based on cost, hospital staffing restrictions, and patient convenience.
Tubal and Pelvic Adhesions
In vitro fertilization (IVF) is the first-line treatment for bilateral tubal factor infertility. Tubal corrective surgeries have worse pregnancy outcomes and have an increased risk of ectopic pregnancy. Women with severe tubal disease, including hydrosalpinx, are encouraged to have a bilateral salpingectomy to increase the pregnancy rate of IVF. For women with mild distal tubal disease, fimbrioplasty is an option to allow for multiple pregnancies without IVF. One small study showed that for mild tubal disease, the pregnancy rate was equal to IVF but the risk of ectopic pregnancy was 15% compared to 0.7% for IVF treatment.
The patients with a prior bilateral salpingectomy or tubal ligation for contraception are an important tubal factor population. It is always important for healthcare providers to discuss the risk of regret with all women who desire tubal ligation. The chance of pregnancy after tubal reanastomosis depends on the patient's age, the type of ligation, and the tubal length available. Younger women who had a ring or a clip with more than 4 cm of tubal length are the best candidates and have comparable pregnancy rates to IVF. However, time to pregnancy is significantly longer following tubal surgery as compared to IVF.
There is unclear evidence on the effect of leiomyomas on infertility and live birth rates. It is recommended that the patient receive a complete infertility workup prior to further investigation into fibroids. The most important aspect of fibroids is the location. Fibroids that impinge on the endometrium and distort the uterine cavity result in impaired implantation and increased miscarriage rates. Women with submucosal or submucosal-intramural fibroids that distort the uterine cavity have been proven to have decreased pregnancy rates. With the removal of these fibroids, the pregnancy, and live birth rates increase. The first-line treatment for removal of the most detrimental fibroids is operative hysteroscopy. Other uterine pathologies like uterine synechiae and septa are more related to recurrent pregnancy loss but are capable of causing infertility. Operative hysteroscopy has shown a marked reduction in pregnancy loss for women with both synechiae and septa. Asymptomatic polyps have also been shown to cause infertility. There was one study that showed a polypectomy on asymptomatic infertile women before IUI increased pregnancy rates from 28% to 63%.
This section will discuss an overview of the IVF procedures without discussion of medication protocols, as the most effective treatment option for infertility. Step 1 is controlled ovarian hyperstimulation with injectable gonadotropins, most commonly. Thirty-six hours after a trigger shot, or HCG injection, a specialist will perform a transvaginal ultrasonography-guided needle aspiration and oocyte retrieval. After retrieval, the oocytes are transferred to a special media, and normal sperm is transferred to the dish for insemination. If there is abnormal sperm, intracytoplasmic sperm injection (ICSI) is performed. ICSI is a procedure that places a single spermatozoon directly into the egg cytoplasm. After fertilization, the embryo is assessed and graded. The embryos are then transferred on Day 3 or Day 5. Preimplantation genetic testing (PGT) is an additional IVF procedure that helps detect known parental genetic mutations or balanced translocation. Additionally, PGT can also be used to detect aneuploidy, both monosomies, and trisomies, from all 23 chromosome pairs. Apart from a known parental carrier for a genetic mutation or balanced translocation, PGT likely is beneficial for advanced maternal age, repeated IVF failures with high-grade embryos, recurrent pregnancy loss, and unexplained infertility.
Infertility is a highly complex disorder with significant effects on the couple as a whole. It is important to remember that there can be, and regularly are, multiple causes to infertility. The differential diagnosis for infertility can be extensive, and a thorough workup is required to ensure no harmful disease process is missed. Due to the expansive nature of this discussion, the manuscript will focus on the differential diagnosis for PCOS, due to its high prevalence in the infertile population.
The differential diagnosis for patients with suspected PCOS includes:
The investigation of PCOS should include total testosterone, DHEA-S, and 17-Hydroxyprogesterone for evaluation of a virilizing ovarian or adrenal tumor or nonclassical congenital adrenal hyperplasia (CAH). There is a suggestion that DHEA-S should only be reserved for women with severe virilization because an asymptomatic, slightly elevated DHEA-S level does not affect management. Additionally, prolactin and thyroid-stimulating hormone should also be measured.
The clinical signs and further evaluation of these disorders are outside the scope of this paper.
This section will cover the pregnancy rates per cycle for each of the treatment modalities. The data are mostly from the evaluation of unexplained infertility but is also consistent for known causes of infertility. The rates of IVF will vary drastically according to multiple individual factors. The following pregnancy rates were collected from a retrospective analysis of 45 separate studies:
Letrozole alone and letrozole with IUI result in similar pregnancy rates as CC plus IUI and can be used for women who IVF is not an option and have failed CC plus IUI.
In 2009, a study showed that in women who failed CC plus IUI should go straight to IVF instead of gonadotropins plus IUI prior to IVF. This study resulted in less time to achieve pregnancy, fewer treatment cycles, and lower total financial cost per delivery. The IVF pregnancy rates have increased since the paper reported above; however, the data still proves the main point that IVF results in the highest pregnancy rates of all treatment options.
The research above suggests that providers can use clomiphene alone as a first-line treatment for infertility. This is no longer true. In 2008, a randomized control trial showed that clomiphene alone had lower live birth rates than expectant management, respectively 14% and 17%. This paper did show that there is a benefit in regards to patient satisfaction versus expectant management; however, a majority of women in both categories were satisfied with their care. In light of this study, ASRM published a committee opinion stating that clomiphene with timed intercourse should be discouraged as a first-line treatment for unexplained infertility.
The three primary complications associated with infertility treatments are multiples, ectopic pregnancy, and ovarian hyperstimulation syndrome.
The risk of multiples has been a problem for artificial reproductive technologies since the inception of the practice. In the U.S., 32% of ART pregnancies were multiples compared to 3.4% of naturally conceived births. In 2009 according to the CDC, the chances of singleton, twin, or higher-order pregnancies with IVF fresh embryo transfer were 62%, 29%, 3%, respectively. The oral ovarian induction agents, clomiphene and letrozole, have a lower risk of multiple gestations compared to gonadotropins with the percentages of twins, triplets, and quadruplets of 7%, 0.5%, 0.3% respectively. Gonadotropins have a 13% chance of multiple gestations, including triplets.
Currently, the ASRM and CDC have strongly promoted the use of elective single embryo transfer eSET for good prognosis patients. With the use of eSET, the rates of twins and triplets as dropped to less than 1%. Additionally, there is active debate if gonadotropins should be used for ovulation induction outside of an IVF protocol due to the high risk of multiples. As the use of IVF increases, the use of gonadotropins in conjunction with IUI will likely continue to decrease.
Ectopic pregnancy following treatment of infertile patients is another risk, which requires extensive counseling. There is a two-to threefold increase of ectopic pregnancies among infertility patients. This is thought to be associated with a high percentage of tubal factor infertility. The highest associated risk of ectopic pregnancy is after a tubal surgery to correct tubal factor infertility. Rates of ectopic pregnancy following tubal reconstructive surgery is approximately 9%, with other reports as high as 30%. The risk of ectopic pregnancy with IVF fresh embryo transfer is higher than frozen embryo transfer, but the overall rate of ectopic pregnancies with IVF is roughly 1.3%. There does not seem to be an increase in ectopic pregnancies with the use of ovulation induction agents combined with IUI versus natural conception; however, in a large study comparing the ovulation induction agents: clomiphene, letrozole, and gonadotropins had ectopic pregnancy rates of 4%, 6%, and 8%, respectively.
Ovarian Hyperstimulation Syndrome (OHSS)
This is an iatrogenic complication of controlled ovarian hyperstimulation that results in a broad range of signs and symptoms, ranging from abdominal distention, nausea, vomiting, enlarged ovaries, third-spacing of fluids, renal failure, and venous thrombosis, acute respiratory distress syndrome, electrolyte derangements, cardiac arrhythmias, and sepsis. If severe OHSS is not treated and monitored, mortality can result from the listed complications. The different stages of OHSS are classified by Golan et al. in 1989. The underlying pathophysiological feature is increased capillary permeability, resulting in a fluid shift into the third space. Women at the highest risk of developing OHSS are those patients with greater than 20 mature follicles who also receive an HCG trigger shot. The incidence of moderate and severe OHSS with IVF ranges from 6% to 1%, respectively. The diagnosis, prevention, and management of OHSS are outside the scope of this manuscript.
Women should see their providers for a referral to an infertility subspecialist if they are unable to achieve pregnancy after 1 year of unprotected timed intercourse, or if she is older 35 years old, 6 months of unprotected timed intercourse. It is important to explain that infertility can be the result of both female and male factors, or a combination of the two. This is important to remember, as the majority of couples with infertility seek care through the female partner's health provider, potentially overlooking the male contribution. The medications and procedures available for female infertility are well studied and have a well-known risk profile. The patient needs to be aware of the risk of multiple gestations, ectopic pregnancy, and OHSS. Finally, the patient needs to understand the odds of pregnancy per treatment cycle for each modality. The inability to conceive, even with IVF, is a possibility that needs to be fully understood before dedicating a large number of resources required for infertility treatment.
As mentioned at the beginning of this article, infertility is a devastating diagnosis and should be considered a disease process by all members of the healthcare team. The author believes the best way to improve the physical, emotional, social, and interpersonal stressors of infertility for the patient is to complete an immediate and thorough investigation into both partners. The evaluation is straightforward and can be completed prior to referral to a fertility subspecialist. This will expedite and enhance the specialist's ability to initiate followup studies and treatments. The use of either clomiphene or letrozole with timed intercourse alone can be used to correct a known cause of anovulation but should not prolong the referral to a subspecialist. All primary care providers need to set realistic expectations of the chances of pregnancy and the possibility of complications when counseling couples suffering from infertility. Lastly, this manuscript is not all-encompassing but provides a basic foundation of knowledge to feel comfortable discussing a patient's family planning goals, initiating an evaluation, and reviewing available treatments.
|||GUTTMACHER AF, Factors affecting normal expectancy of conception. Journal of the American Medical Association. 1956 Jun 30; [PubMed PMID: 13319020]|
|||Infertility Workup for the Women's Health Specialist: ACOG Committee Opinion, Number 781. Obstetrics and gynecology. 2019 Jun; [PubMed PMID: 31135764]|
|||Recent advances in medically assisted conception. Report of a WHO Scientific Group. World Health Organization technical report series. 1992; [PubMed PMID: 1642014]|
|||Chandra A,Copen CE,Stephen EH, Infertility and impaired fecundity in the United States, 1982-2010: data from the National Survey of Family Growth. National health statistics reports. 2013 Aug 14; [PubMed PMID: 24988820]|
|||Mascarenhas MN,Flaxman SR,Boerma T,Vanderpoel S,Stevens GA, National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS medicine. 2012; [PubMed PMID: 23271957]|
|||Santoro N,Filicori M,Crowley WF Jr, Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocrine reviews. 1986 Feb; [PubMed PMID: 3082615]|
|||Ackerman KE,Patel KT,Guereca G,Pierce L,Herzog DB,Misra M, Cortisol secretory parameters in young exercisers in relation to LH secretion and bone parameters. Clinical endocrinology. 2013 Jan; [PubMed PMID: 22671919]|
|||Perkins RB,Hall JE,Martin KA, Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. The Journal of clinical endocrinology and metabolism. 1999 Jun; [PubMed PMID: 10372685]|
|||Hull MG, Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 1987 Sep; [PubMed PMID: 3140583]|
|||Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Oxford, England). 2004 Jan; [PubMed PMID: 14688154]|
|||Fauser BC,Van Heusden AM, Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocrine reviews. 1997 Feb; [PubMed PMID: 9034787]|
|||Baker TG, Radiosensitivity of mammalian oocytes with particular reference to the human female. American journal of obstetrics and gynecology. 1971 Jul 1; [PubMed PMID: 4935165]|
|||Richardson SJ,Senikas V,Nelson JF, Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. The Journal of clinical endocrinology and metabolism. 1987 Dec; [PubMed PMID: 3119654]|
|||Westhoff C,Murphy P,Heller D, Predictors of ovarian follicle number. Fertility and sterility. 2000 Oct; [PubMed PMID: 11020495]|
|||Broekmans FJ,Soules MR,Fauser BC, Ovarian aging: mechanisms and clinical consequences. Endocrine reviews. 2009 Aug; [PubMed PMID: 19589949]|
|||Nelson LM,Anasti JN,Kimzey LM,Defensor RA,Lipetz KJ,White BJ,Shawker TH,Merino MJ, Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. The Journal of clinical endocrinology and metabolism. 1994 Nov; [PubMed PMID: 7962345]|
|||Nelson LM, Clinical practice. Primary ovarian insufficiency. The New England journal of medicine. 2009 Feb 5; [PubMed PMID: 19196677]|
|||Seppälä M,Ranta T,Hirvonen E, Hyperprolactinaemia and luteal insufficiency. Lancet (London, England). 1976 Jan 31; [PubMed PMID: 55535]|
|||Olive DL,Pritts EA, Treatment of endometriosis. The New England journal of medicine. 2001 Jul 26; [PubMed PMID: 11474666]|
|||Prescott J,Farland LV,Tobias DK,Gaskins AJ,Spiegelman D,Chavarro JE,Rich-Edwards JW,Barbieri RL,Missmer SA, A prospective cohort study of endometriosis and subsequent risk of infertility. Human reproduction (Oxford, England). 2016 Jul; [PubMed PMID: 27141041]|
|||Macer ML,Taylor HS, Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstetrics and gynecology clinics of North America. 2012 Dec; [PubMed PMID: 23182559]|
|||Bulun SE, Endometriosis. The New England journal of medicine. 2009 Jan 15; [PubMed PMID: 19144942]|
|||Gupta S,Goldberg JM,Aziz N,Goldberg E,Krajcir N,Agarwal A, Pathogenic mechanisms in endometriosis-associated infertility. Fertility and sterility. 2008 Aug; [PubMed PMID: 18672121]|
|||Holoch KJ,Lessey BA, Endometriosis and infertility. Clinical obstetrics and gynecology. 2010 Jun; [PubMed PMID: 20436320]|
|||Toya M,Saito H,Ohta N,Saito T,Kaneko T,Hiroi M, Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer. Fertility and sterility. 2000 Feb; [PubMed PMID: 10685541]|
|||Weström L,Joesoef R,Reynolds G,Hagdu A,Thompson SE, Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sexually transmitted diseases. 1992 Jul-Aug; [PubMed PMID: 1411832]|
|||Weström L, Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. American journal of obstetrics and gynecology. 1980 Dec 1; [PubMed PMID: 7008604]|
|||Lepine LA,Hillis SD,Marchbanks PA,Joesoef MR,Peterson HB,Westrom L, Severity of pelvic inflammatory disease as a predictor of the probability of live birth. American journal of obstetrics and gynecology. 1998 May; [PubMed PMID: 9609570]|
|||Meyer WR,Castelbaum AJ,Somkuti S,Sagoskin AW,Doyle M,Harris JE,Lessey BA, Hydrosalpinges adversely affect markers of endometrial receptivity. Human reproduction (Oxford, England). 1997 Jul; [PubMed PMID: 9262264]|
|||Van Voorhis BJ,Mejia RB,Schlaff WD,Hurst BS, Is removal of hydrosalpinges prior to in vitro fertilization the standard of care? Fertility and sterility. 2019 Apr [PubMed PMID: 30929723]|
|||Pritts EA, Fibroids and infertility: a systematic review of the evidence. Obstetrical [PubMed PMID: 11496160]|
|||Grimbizis GF,Camus M,Tarlatzis BC,Bontis JN,Devroey P, Clinical implications of uterine malformations and hysteroscopic treatment results. Human reproduction update. 2001 Mar-Apr; [PubMed PMID: 11284660]|
|||Chan YY,Jayaprakasan K,Zamora J,Thornton JG,Raine-Fenning N,Coomarasamy A, The prevalence of congenital uterine anomalies in unselected and high-risk populations: a systematic review. Human reproduction update. 2011 Nov-Dec; [PubMed PMID: 21705770]|
|||Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertility and sterility. 2013 Jan; [PubMed PMID: 23095139]|
|||Optimizing natural fertility. Fertility and sterility. 2008 Nov; [PubMed PMID: 19007604]|
|||Wathen NC,Perry L,Lilford RJ,Chard T, Interpretation of single progesterone measurement in diagnosis of anovulation and defective luteal phase: observations on analysis of the normal range. British medical journal (Clinical research ed.). 1984 Jan 7; [PubMed PMID: 6418326]|
|||Ecochard R,Boehringer H,Rabilloud M,Marret H, Chronological aspects of ultrasonic, hormonal, and other indirect indices of ovulation. BJOG : an international journal of obstetrics and gynaecology. 2001 Aug; [PubMed PMID: 11510707]|
|||Abdalla H,Thum MY, An elevated basal FSH reflects a quantitative rather than qualitative decline of the ovarian reserve. Human reproduction (Oxford, England). 2004 Apr; [PubMed PMID: 15016786]|
|||Smotrich DB,Widra EA,Gindoff PR,Levy MJ,Hall JL,Stillman RJ, Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertility and sterility. 1995 Dec; [PubMed PMID: 7589666]|
|||Dewailly D,Andersen CY,Balen A,Broekmans F,Dilaver N,Fanchin R,Griesinger G,Kelsey TW,La Marca A,Lambalk C,Mason H,Nelson SM,Visser JA,Wallace WH,Anderson RA, The physiology and clinical utility of anti-Mullerian hormone in women. Human reproduction update. 2014 May-Jun; [PubMed PMID: 24430863]|
|||de Vet A,Laven JS,de Jong FH,Themmen AP,Fauser BC, Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertility and sterility. 2002 Feb; [PubMed PMID: 11821097]|
|||Toner JP,Seifer DB, Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertility and sterility. 2013 Jun; [PubMed PMID: 23548941]|
|||Steiner AZ,Pritchard D,Stanczyk FZ,Kesner JS,Meadows JW,Herring AH,Baird DD, Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017 Oct 10; [PubMed PMID: 29049585]|
|||Vrontikis A,Chang PL,Kovacs P,Lindheim SR, Antral follice counts (AFC) predict ovarian response and pregnancy outcomes in oocyte donation cycles. Journal of assisted reproduction and genetics. 2010 Jul [PubMed PMID: 20467804]|
|||Mol BW,Swart P,Bossuyt PM,van der Veen F, Is hysterosalpingography an important tool in predicting fertility outcome? Fertility and sterility. 1997 Apr; [PubMed PMID: 9093191]|
|||Papaioannou S,Bourdrez P,Varma R,Afnan M,Mol BW,Coomarasamy A, Tubal evaluation in the investigation of subfertility: a structured comparison of tests. BJOG : an international journal of obstetrics and gynaecology. 2004 Dec; [PubMed PMID: 15663113]|
|||Luttjeboer F,Harada T,Hughes E,Johnson N,Lilford R,Mol BW, Tubal flushing for subfertility. The Cochrane database of systematic reviews. 2007 Jul 18; [PubMed PMID: 17636730]|
|||Seshadri S,El-Toukhy T,Douiri A,Jayaprakasan K,Khalaf Y, Diagnostic accuracy of saline infusion sonography in the evaluation of uterine cavity abnormalities prior to assisted reproductive techniques: a systematic review and meta-analyses. Human reproduction update. 2015 Mar-Apr; [PubMed PMID: 25505226]|
|||Frisch RE, The right weight: body fat, menarche and ovulation. Bailliere's clinical obstetrics and gynaecology. 1990 Sep; [PubMed PMID: 2282736]|
|||Yen SS,Rebar R,Vandenberg G,Ehara Y,Siler T, Pituitary gonadotrophin responsiveness to synthetic LRF in subjects with normal and abnormal hypothalamic-pituitary-gonadal axis. Journal of reproduction and fertility. Supplement. 1973 Dec; [PubMed PMID: 4599401]|
|||Abraham S,Mira M,Llewellyn-Jones D, Should ovulation be induced in women recovering from an eating disorder or who are compulsive exercisers? Fertility and sterility. 1990 Mar; [PubMed PMID: 2407567]|
|||Berga SL,Marcus MD,Loucks TL,Hlastala S,Ringham R,Krohn MA, Recovery of ovarian activity in women with functional hypothalamic amenorrhea who were treated with cognitive behavior therapy. Fertility and sterility. 2003 Oct; [PubMed PMID: 14556820]|
|||Crosignani PG,Colombo M,Vegetti W,Somigliana E,Gessati A,Ragni G, Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Human reproduction (Oxford, England). 2003 Sep; [PubMed PMID: 12923151]|
|||Mutsaerts MA,van Oers AM,Groen H,Burggraaff JM,Kuchenbecker WK,Perquin DA,Koks CA,van Golde R,Kaaijk EM,Schierbeek JM,Oosterhuis GJ,Broekmans FJ,Bemelmans WJ,Lambalk CB,Verberg MF,van der Veen F,Klijn NF,Mercelina PE,van Kasteren YM,Nap AW,Brinkhuis EA,Vogel NE,Mulder RJ,Gondrie ET,de Bruin JP,Sikkema JM,de Greef MH,ter Bogt NC,Land JA,Mol BW,Hoek A, Randomized Trial of a Lifestyle Program in Obese Infertile Women. The New England journal of medicine. 2016 May 19; [PubMed PMID: 27192672]|
|||Wu CH,Winkel CA, The effect of therapy initiation day on clomiphene citrate therapy. Fertility and sterility. 1989 Oct; [PubMed PMID: 2806595]|
|||Cole PA,Robinson CH, Mechanism and inhibition of cytochrome P-450 aromatase. Journal of medicinal chemistry. 1990 Nov; [PubMed PMID: 2231592]|
|||ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice. Obstetrics and gynecology. 2018 Jun; [PubMed PMID: 29794680]|
|||Casper RF,Mitwally MF, Review: aromatase inhibitors for ovulation induction. The Journal of clinical endocrinology and metabolism. 2006 Mar; [PubMed PMID: 16384846]|
|||Weiss NS,Nahuis MJ,Bordewijk E,Oosterhuis JE,Smeenk JM,Hoek A,Broekmans FJ,Fleischer K,de Bruin JP,Kaaijk EM,Laven JS,Hendriks DJ,Gerards MH,van Rooij IA,Bourdrez P,Gianotten J,Koks C,Lambalk CB,Hompes PG,van der Veen F,Mol BWJ,van Wely M, Gonadotrophins versus clomifene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomifene failure (M-OVIN): a randomised, two-by-two factorial trial. Lancet (London, England). 2018 Feb 24; [PubMed PMID: 29273245]|
|||Ludwig M,Doody KJ,Doody KM, Use of recombinant human chorionic gonadotropin in ovulation induction. Fertility and sterility. 2003 May; [PubMed PMID: 12738494]|
|||Cantineau AE,Janssen MJ,Cohlen BJ, Synchronised approach for intrauterine insemination in subfertile couples. The Cochrane database of systematic reviews. 2010 Apr 14; [PubMed PMID: 20393953]|
|||Johnson NP,Mak W,Sowter MC, Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. The Cochrane database of systematic reviews. 2004; [PubMed PMID: 15266464]|
|||Audebert A,Pouly JL,Bonifacie B,Yazbeck C, Laparoscopic surgery for distal tubal occlusions: lessons learned from a historical series of 434 cases. Fertility and sterility. 2014 Oct; [PubMed PMID: 25150389]|
|||Boeckxstaens A,Devroey P,Collins J,Tournaye H, Getting pregnant after tubal sterilization: surgical reversal or IVF? Human reproduction (Oxford, England). 2007 Oct; [PubMed PMID: 17670765]|
|||Pritts EA,Parker WH,Olive DL, Fibroids and infertility: an updated systematic review of the evidence. Fertility and sterility. 2009 Apr; [PubMed PMID: 18339376]|
|||Casini ML,Rossi F,Agostini R,Unfer V, Effects of the position of fibroids on fertility. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2006 Feb; [PubMed PMID: 16603437]|
|||March CM,Israel R, Gestational outcome following hysteroscopic lysis of adhesions. Fertility and sterility. 1981 Oct; [PubMed PMID: 6269905]|
|||Pérez-Medina T,Bajo-Arenas J,Salazar F,Redondo T,Sanfrutos L,Alvarez P,Engels V, Endometrial polyps and their implication in the pregnancy rates of patients undergoing intrauterine insemination: a prospective, randomized study. Human reproduction (Oxford, England). 2005 Jun; [PubMed PMID: 15760959]|
|||Milczarek M,Kucharska A,Borowiec A, Difficulties in diagnostics of polycystic ovary syndrome in adolescents - a preliminary study. Pediatric endocrinology, diabetes, and metabolism. 2019 [PubMed PMID: 31769270]|
|||Derksen J,Nagesser SK,Meinders AE,Haak HR,van de Velde CJ, Identification of virilizing adrenal tumors in hirsute women. The New England journal of medicine. 1994 Oct 13; [PubMed PMID: 8084355]|
|||Azziz R,Dewailly D,Owerbach D, Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. The Journal of clinical endocrinology and metabolism. 1994 Apr; [PubMed PMID: 8157702]|
|||[PubMed PMID: 31973903]|
|||Liu A,Zheng C,Lang J,Chen W, Letrozole versus clomiphene citrate for unexplained infertility: a systematic review and meta-analysis. The journal of obstetrics and gynaecology research. 2014 May; [PubMed PMID: 24754848]|
|||Reindollar RH,Regan MM,Neumann PJ,Levine BS,Thornton KL,Alper MM,Goldman MB, A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertility and sterility. 2010 Aug; [PubMed PMID: 19531445]|
|||Use of clomiphene citrate in infertile women: a committee opinion. Fertility and sterility. 2013 Aug; [PubMed PMID: 23809505]|
|||Sunderam S,Kissin DM,Zhang Y,Folger SG,Boulet SL,Warner L,Callaghan WM,Barfield WD, Assisted Reproductive Technology Surveillance - United States, 2016. Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002). 2019 Apr 26; [PubMed PMID: 31022165]|
|||Yu B,Vega M,Zaghi S,Fritz R,Jindal S,Buyuk E, Comparison of perinatal outcomes following frozen embryo transfer cycles using autologous versus donor oocytes in women 40 to 43 years old: analysis of SART CORS data. Journal of assisted reproduction and genetics. 2018 Nov; [PubMed PMID: 30128819]|
|||Hansen KR,He AL,Styer AK,Wild RA,Butts S,Engmann L,Diamond MP,Legro RS,Coutifaris C,Alvero R,Robinson RD,Casson P,Christman GM,Huang H,Santoro N,Eisenberg E,Zhang H, Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination. Fertility and sterility. 2016 Jun; [PubMed PMID: 26949110]|
|||Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertility and sterility. 2017 Apr [PubMed PMID: 28292618]|
|||Li C,Zhao WH,Zhu Q,Cao SJ,Ping H,Xi X,Qin GJ,Yan MX,Zhang D,Qiu J,Zhang J, Risk factors for ectopic pregnancy: a multi-center case-control study. BMC pregnancy and childbirth. 2015 Aug 22; [PubMed PMID: 26296545]|
|||Londra L,Moreau C,Strobino D,Garcia J,Zacur H,Zhao Y, Ectopic pregnancy after in vitro fertilization: differences between fresh and frozen-thawed cycles. Fertility and sterility. 2015 Jul; [PubMed PMID: 25956363]|
|||Diamond MP,Legro RS,Coutifaris C,Alvero R,Robinson RD,Casson P,Christman GM,Ager J,Huang H,Hansen KR,Baker V,Usadi R,Seungdamrong A,Bates GW,Rosen RM,Haisenleder D,Krawetz SA,Barnhart K,Trussell JC,Ohl D,Jin Y,Santoro N,Eisenberg E,Zhang H, Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. The New England journal of medicine. 2015 Sep 24; [PubMed PMID: 26398071]|
|||Golan A,Ron-el R,Herman A,Soffer Y,Weinraub Z,Caspi E, Ovarian hyperstimulation syndrome: an update review. Obstetrical [PubMed PMID: 2660037]|
|||Delvigne A,Rozenberg S, Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human reproduction update. 2002 Nov-Dec; [PubMed PMID: 12498425]|